Autres langues Chabiotech Co.,Ltd.

Actions

A085660

KR7085660009

Cours en clôture Korea S.E. Autres places de cotation 00:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
16 900 ^KRW	-0,65 %		+2,36 %	-13,73 %

2023

CHA Biotech Co. publie ses résultats pour le premier trimestre clos le 31 mars 2023

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

CHA Biotech to Partner with Subsidiary to Advance NK Cell Therapy	08/01
CHA Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23
Chronic Lower Back Pain Pipeline Offers Novel Treatment Options \| 10+ Companies & 10+ Drugs	06/12/22
CHA Biotech : Unit Signs Contract with Sartorius for Viral Vectors Process Technology	21/10/21
CHA Biotech Co., Ltd. announced that it has received KRW 75 billion in funding from a group of investors	19/06/20
CHA Biotech Co., Ltd. announced that it expects to receive KRW 75 billion in funding from a group of investors	17/06/20
Astellas Institute for Regenerative Medicine acquired remaining 50% stake in Stem Cell & Regenerative Medicine International, Inc from CHA Biotech Co., Ltd. for $46.7 million.	25/06/19
Chabiotech To Divest Biotechnology And Medicine And Medical Supplies	12/04/18
Sorrento Therapeutics to Form Joint Venture with CHA Biotech Co	11/08/16
Sorrento Therapeutics, Inc. to Form Joint Venture with CHA Biotech Co., Ltd. to Develop and Commercialize Natural Killer Cell Therapies	02/08/16
CHA Biotech Co., Ltd. announced that it has received KRW 44 billion in funding from a group of investors	21/04/16
CHA Biotech Co., Ltd. announced that it expects to receive KRW 44 billion in funding from Kyunghee Industry Co. Ltd. and other investors	19/04/16
Closed Merger/Acquisition Transaction â€“ Target: Chadiostech Co., Ltd.; Buyer(s): Da Vinci Capital Management Ltd., The European Bank for Reconstruction and Development, Investment Arm; Seller(s): CHA Biotech Co., Ltd., Kyunghee Industry Co. Ltd., Sungkwang Medical Foundation, Endowment Arm; Transaction Size: KRW23503.27 mm	29/12/15
The Da Vinci CIS Private Sector Growth Fund (Fund I), Da Vinci Eurasian Financial Infrastructure Fund (Fund II) and Da Vinci No. 3 Investment Fund (Fund III) of Da Vinci Capital Management Ltd. and The European Bank for Reconstruction and Development, Investment Arm, Chang-Mi Bin, Jung-Seok Oh and Jung-Seok Kang entered into a contract to acquire 22.66% stake in Chadiostech Co., Ltd. from Gwang-Yeol Cha, 8 other individuals, CHA Biotech Co., Ltd., Kyunghee Indus	30/11/15
CHA Healthcare Operation Co., Ltd. cancelled the acquisition of Cha Medical Service Co., Ltd. from CHA Bio&Diostech Inc. and others.	26/11/15
CHA-Meditech Co., Ltd. acquired CHA-BioMed Co. Ltd from CHA Bio&Diostech Inc. and other sellers.	30/06/15
CHA Healthcare Operation Co., Ltd. agreed to acquire Cha Medical Service Co., Ltd. from CHA Bio&Diostech Inc. and others.	26/11/14
CHA Bio & Diostech Co., Ltd. completed the spin-off of camera lens and optical science business division for KRW 140 billion	02/05/14
CHA Bio & Diostech Co., Ltd. agreed to spin-off camera lens and optical science business division.	26/12/13
Cha Bio&Diostech Files Investigational New Drug with Korean FDA for PLX Cells	08/07/13

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Chabiotech Co.,Ltd.

Actions

A085660

KR7085660009

Autres langues

Filtres